Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures
Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Both buccal and intramuscular midazolam have been used to control seizures with variable succuss rates and side effects.
In this study the investigators are going to assign patient randomly to receive either buccal or intramuscular midazolam. Then will compare both efficacy and side effect in both groups.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Doha, Qatar, 3050
- Hamad Medical Corporation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children 6 month to 14 years who will be presented to the pediatric emergency or attended by emergency medical service who have active seizure and had no intravenous access would be eligible for the study.
Exclusion Criteria:
- Cardiac arrest
- Head trauma
- Drowning
- Congenital heart disease
- Inborn errors of metabolism
- Electrolyte imbalance (hypocalcaemia, hyponatremia and hypoglycemia)
- Hemodynamic instability
- Allergy to benzodiazepines
- Focal seizures with preserved level of consciousness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Buccal midazolam
Study subject will receive buccal midazolam and intramuscular placebo.
The dose of buccal midazolam is 0.3 mg/kg
|
Study subject will receive Buccal midazolam, Intramuscular placebo.
|
|
Active Comparator: intramuscular midazolam
Study subject will receive intramuscular midazolam and buccal placebo.
The dose of intramuscular midazolam is 0.25 mg/kg.
|
Study subject will receive Intramuscular midazolam,Buccal placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cessation of seizure activity five minutes after treatment with study medication.
Time Frame: five minutes
|
Cessation of abnormal motor activity with regaining of consciousness.
|
five minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Major side effects.
Time Frame: 2 hours after cessation of seizures.
|
2 hours after cessation of seizures.
|
|
Duration of seizure.
Time Frame: 5 minutes
|
5 minutes
|
|
Recurrence of seizure activity within one hour after treatment with study medication.
Time Frame: one hour
|
one hour
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Seizures
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
Other Study ID Numbers
Other Study ID Numbers
- 14-00050
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.